13 March 2023
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Change of Accounting Reference Date
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a change to its accounting reference date and financial year end from 31 March to 30 September with immediate effect. Going forward the annual and interim reports will be published each year for the 12 months to 30 September and 6 months to 31 March respectively.
As a result of this change in the accounting reference date, Nuformix's reporting timetable will be as follows:
· Unaudited interim results for the 12 months to 31 March 2023 to be released by 30 June 2023;
· Audited report and accounts for the 18 month period to 30 September 2023 published by 31 January 2023; and
· Unaudited interim results for the six months to 31 March 2024 to be released by 30 June 2024.
Enquiries:
| Nuformix plc |
|
| Dr Dan Gooding, Executive Director
| Via IFC Advisory
|
| Stanford Capital Partners Limited |
|
| Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
| John Howes (Corporate Broking) | +44 (0) 20 3650 3652
|
| IFC Advisory Limited |
|
| Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
